1. Biotechnology-derived cardiovascular therapeutics and toxicity

   • Y. James

   BriefCommunication Pages: 1 - 3

2. Commercial development considerations for biotechnology-derived therapeutics

   • B. J. Marafino Jr.
   • M. K. Pugsley

   OriginalPaper Pages: 5 - 12

3. Direct thrombin inhibitors in cardiac disease

   • Jeffrey I. Weitz
   • Eric R. Bates

   OriginalPaper Pages: 13 - 25

4. Translation of PDGF cardioprotective pathways

   • Jay M. Edelberg
   • Dongqing Cai
   • Munira Xaymardan

   OriginalPaper Pages: 27 - 35

5. Nesiritide

   • Alan S. Maisel

   OriginalPaper Pages: 37 - 42

6. Inhibitors of the complement system currently in development for cardiovascular disease

   • M. K. Pugsley
   • M. Abramova
   • W. S. Ammons

   OriginalPaper Pages: 43 - 69

7. Adenosine receptors and cardiovascular disease

   • E. S. Hayes

   OriginalPaper Pages: 71 - 88